Medicines manufactured without license seized in Himachal Pradesh

Medicines manufactured without license seized in Himachal Pradesh

Una , Medicines worth ₹six lakh were seized from a pharma unit operating without license in Bathu area of Himachal’s Una district, officials said on Friday.

The raid was conducted by the Una police along with the drug department at the pharma unit on Thursday night. The unit, which had been closed 14 years ago, was illegally manufacturing drugs.

Acting on a tip-off, a team led by Special Investigation Branch in-charge Sunil Kumar Sankhyan raided the unit and illegally manufactured tablets were found in the premises.

The factory’s license was revoked in 2011 after serious deficiencies were found. Despite this, production continued without any valid permission. The seized drugs were for general use and no banned drugs were found, Drug Inspector Pankaj Gautam said.

Action is being taken against the factory owner under the Drugs and Cosmetics Act and an investigation is underway to determine where the drugs were supplied and who else is involved, he added.

Superintendent of Police, Una, Amit Yadav said that violations of regulations will not be tolerated and action will continue. The drug department will now investigate the quality, validity and documentation of the seized batch.

After Bathu, the joint team also conducted a surprise inspection of another pharma unit located on Karmapur-Laldi Road. The unit was found closed for a long time, and no activity was found on the premises.

Nearly 50 pharmaceutical industries in the state are closed, but some of them are manufacturing drugs illegally. Recently, a case came to light in Baddi where a defunct company illegally manufactured drugs in the name of an Assamese factory.

Investigation has revealed that the original pharmaceutical company is closed and no longer manufactures the drug. The company operator has been sent to judicial custody, while the supplier remains at large.

Following this incident, the Drug Control Administration ‘s Anti-Narcotics Task Force had conducted extensive raids across the state on Wednesday and 20 industries were simultaneously raided in Sirmaur, Una, Kangra, and Solan districts.

At four locations, irregularities were found and production activities were continuing despite the closure.

State Drug Controller Manish Kapoor said the administration has a zero-tolerance policy towards violations. He warned that any company found to be disobeying orders would face strict action.

Related Posts

Over 9,000 deaths due to respiratory diseases in Delhi

New Delhi:  The national capital recorded 9,211 deaths due to respiratory diseases in 2024, up from 8,801 in 2023, continuing an upward trend seen over the past few years, according…

Nebuliser, inhaler demand for children jumps by up to 60 pc in Delhi winters: Survey

New Delhi:  The demand for nebulisers, inhalers and respiratory medicines for children has surged sharply in Delhi during winter months, with chemists reporting spikes of up to 60 per cent…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Over 9,000 deaths due to respiratory diseases in Delhi

Over 9,000 deaths due to respiratory diseases in Delhi

Nebuliser, inhaler demand for children jumps by up to 60 pc in Delhi winters: Survey

Nebuliser, inhaler demand for children jumps by up to 60 pc in Delhi winters: Survey

Pharma company, its employees convicted for ‘illegal diversion” of meth precursor abroad

Pharma company, its employees convicted for ‘illegal diversion” of meth precursor abroad

Ayurveda practitioner fined by ISM Council for violation of professional ethics

Ayurveda practitioner fined by ISM Council for violation of professional ethics

Administering rabies vaccine at the wrong site can be fatal: Shoulders or thighs only, warn experts

Administering rabies vaccine at the wrong site can be fatal: Shoulders or thighs only, warn experts

Delhi HC allows Zydus to sell biosimilar of blockbuster anti-cancer drug Nivolumab

Delhi HC allows Zydus to sell biosimilar of blockbuster anti-cancer drug Nivolumab